PE Biosystems Eyeing Spin-out Of Expanded Molecular Diagnostic Business
This article was originally published in The Gray Sheet
Executive Summary
PE Corp. is looking to leverage the capabilities of its two component business units, PE Biosystems and Celera Genomics, to increase the company's presence in the molecular diagnostics field, most likely through a spin-out of the new operation.